

# BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY

Fifth Edition

Volume I: Principles and Practice

Edited by

**Manfred E. Wolff**

ImmunoPharmaceutics, Inc.  
San Diego, California



A WILEY-INTERSCIENCE PUBLICATION

JOHN WILEY & SONS, Inc., New York · Chichester · Brisbane · Toronto · Singapore

**Apotex v. Auspex**  
**IPR2021-01507**

**Apotex Ex. 1022**



*Notice Concerning Trademark or Patent Rights.*

The listing or discussion in this book of any drug in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as a grant of, or authority to exercise, or an infringement of, any right or privilege protected by such patent or trademark.

This text is printed on acid-free paper.

Copyright © 1995 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, 605 Third Avenue, New York, NY 10158-0012.

*Library of Congress Cataloging in Publication Data:*

Burger, Alfred, 1905-  
 [Medicinal chemistry]  
 Burger's medicinal chemistry and drug discovery. -- 5th ed. /  
 edited by Manfred E. Wolff.  
 p. cm.  
 "A Wiley-Interscience publication."  
 Contents: v. 1. Principles and practice  
 Includes bibliographical references and index.  
 ISBN 0-471-57556-9  
 1. Pharmaceutical chemistry. I. Wolff, Manfred E. II. Title.  
 III. Title: Medicinal chemistry and drug discovery.  
 RS403.B8 1994  
 615'.19--dc20

94-12687

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

Apotex Ex. 1022

## CHAPTER NINE

# From Discovery to Market: The Development of Pharmaceuticals

JAN I. DRAYER  
JAMES P. BURNS

G. H. Besselaar Associates  
Princeton, New Jersey, USA

### CONTENTS

- 1 Introduction, 252
  - 1.1 Evolution of drug development, 253
    - 1.1.1 Regulatory environment, 253
    - 1.1.2 Scientific environment, 255
    - 1.1.3 Commercial environment, 256
  - 1.2 Costs of drug development, 257
- 2 The Drug Development Process, 258
  - 2.1 Chemistry, 259
    - 2.1.1 Preformulation, 261
    - 2.1.2 Product development/formulation, 261
    - 2.1.3 Phase 2 and phase 3 clinical supplies, 261
    - 2.1.4 Containers, 262
    - 2.1.5 Closures, 262
  - 2.2 Preclinical studies, 264
    - 2.2.1 Acute toxicity, 265
    - 2.2.2 Subacute toxicity studies, 265
    - 2.2.3 Chronic toxicity studies, 266
    - 2.2.4 Carcinogenicity studies, 266
    - 2.2.5 Mutagenicity studies, 267
    - 2.2.6 Reproduction studies, 267
    - 2.2.7 Special toxicity studies, 267
  - 2.3 Transition from preclinical to clinical, 268
  - 2.4 Planning the drug development process, 269
    - 2.4.1 Assumptions, 269
    - 2.4.2 Defining the development strategy, 271
    - 2.4.3 The drug development master plan, 272

*Burger's Medicinal Chemistry and Drug Discovery*,  
Fifth Edition, Volume 1: Principles and Practice,  
Edited by Manfred E. Wolff.  
ISBN 0-471-57556-9 © 1995 John Wiley & Sons, Inc.

251

Apotex Ex. 1022

- 2.4.4 Critical components of the clinical part of the drug development master plan, 275
- 2.5 Clinical research; the conduct of clinical trials, 279
  - 2.5.1 Phase 1 clinical research, 280
  - 2.5.2 Phase 2 and phase 3 clinical research, 282
  - 2.5.3 Periapproval clinical trial programs, 286
  - 2.5.4 Development of the final protocol and case report forms, 286
  - 2.5.5 Investigator selection, 288
  - 2.5.6 Monitoring of studies, 290
  - 2.5.7 Evaluation of adverse events in clinical trials, 291
  - 2.5.8 Ethical considerations in clinical research, 292
  - 2.5.9 Clinical trial reports, 295
  - 2.5.10 When to stop the development of a drug, 295
  - 2.5.11 Regulatory review during the conduct of clinical trials, 296
    - 2.5.11.1 End of phase 2 and phase 3 conferences, 297
    - 2.5.11.2 FDA interactions under subpart E, 297
    - 2.5.11.3 Regulatory approval process, 298
    - 2.5.11.4 Approval and launch, 299

## 1 INTRODUCTION

Through the early years of this century, most drugs or medicines that were sold to the public were little more than home remedies or extracts of various natural products including barks and flowers, that owed their activity more to the alcoholic content of the elixir than to the actual activity of the product. With the advent of modern drug discovery technology and the ability to synthesize chemicals with specific pharmacologic activities, drug development has evolved considerably from that point.

This chapter addresses the process of modern drug development from the point where a candidate drug has emerged from the drug discovery process, up through regulatory approval, and beyond into periapproval and post-marketing activities. Although the development of drugs is becom-

ing an increasingly global endeavor, the focus of this discussion is the U.S. Food and Drug Administration (FDA) and the associated steps in drug development necessary to satisfy the FDA, the regulatory body that holds the power of approval or disapproval for drugs on the U.S. market. The FDA also has statutory authority for approval of other therapeutic/diagnostic modalities such as biologics and devices; however, this chapter will focus exclusively on drug development even though there are many concepts of drug development that are applicable to both biologics and devices.

During drug development, not only does the FDA evaluate the scientific merit of the data presented in support of approval of a drug, but also the labeling or package insert which contains the directions for use of the approved drug. The labeling in-

structs physicians about the mechanism of action of the drug; the specific indication(s) approved for the drug; any special precautions that patients should be advised to take when using the drug; any safety issues that have arisen in animal or human testing with the drug that physicians and patients should be aware of; potential adverse effects and their incidence that have been known to occur in clinical studies and could therefore occur in clinical use; any potential for abuse or addiction; and dosing recommendations (see Table 9.1). The content of this labeling determines how the approved drug can be marketed and promoted. As such, labeling becomes a crucial document that can ultimately define the commercial success of the drug and the blueprint upon which drug development should be planned and executed. The evolution of that drug development process is the starting point of this chapter.

### 1.1 Evolution of Drug Development

Three factors have played a major role in shaping the evolution of drug development. They are: Regulatory Environment, Scientific Environment, and Industrial/Commercial Environment. Each of these en-

**Table 9.1 Standard Sections of a Package Insert**

- 
- Description
  - Clinical Pharmacology
  - Indications and Usage
  - Contraindications
  - Warnings
  - Precautions
  - Adverse Reactions
  - Drug Abuse and Dependence
  - Overdosage
  - Dosage and Administration
  - How Supplied
- 

vironments has had an impact, but not necessarily at the same time or to the same degree. They have evolved at their own pace.

**1.1.1 REGULATORY ENVIRONMENT.** During drug discovery, only general federal laws, regulations, or guidelines regarding environmental protection, animal care and scientific misconduct govern the basic research process. However, once a chemical becomes a candidate for development to ultimate commercialization, the company developing this product must be aware of the specific laws, regulations, and guidelines that are appropriate to the development of such products so that the results of the investigations conducted will be acceptable to the Food and Drug Administration (FDA) and health regulatory authorities in other countries as necessary.

The involvement of the Federal government in the regulation of drugs and the close relationship of this regulation of drugs with foods, dates back more than 100 years. At that time, the practice of medicine in the United States was generally limited to providing advice on the consumption of various herbs, spices, and other food substances that were taken to achieve the desired result; for instance, maintenance of good health or improved health. Because of this differentiation, the U.S. Department of Agriculture has been the federal agency that was initially responsible for monitoring the potential adverse health effects resulting from adulterated food products. Specifically, this responsibility fell to the Division of Chemistry within the Department of Agriculture and this department has been the entity which is the direct forerunner of the present Food and Drug Administration.

The regulation of drugs in the United States has largely been shaped by three major events. First, in the early 1900s, there were widespread abuses in the food industry, especially the meat packing indus-

**Apotex Ex. 1022**

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.